Evotec SE continued to build its global service business in the first half of 2021 with the completion of a new biologics plant in the US, ownership of an R&D site in Verona, Italy, and new and expanded partnerships with pharma companies to co-develop compounds for multiple diseases. At the end of the first half, the company had more than 130 co-owned assets in its portfolio, potentially capable of delivering income in the form of royalty payments from 2024 onwards.
